Infinity Pharmaceuticals Stock Earnings Per Share
| INFIDelisted Stock | USD 0.04 0.03 42.86% |
Infinity Pharmaceuticals fundamentals help investors to digest information that contributes to Infinity Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Infinity Stock. The fundamental analysis module provides a way to measure Infinity Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Infinity Pharmaceuticals stock.
Infinity |
Infinity Pharmaceuticals Company Earnings Per Share Analysis
Infinity Pharmaceuticals' Earnings per Share (EPS) denotes the portion of a company's earnings that is allocated to each share of common stock. To calculate Earnings per Share investors will need to take a company's net income, subtract any dividends for preferred stock, and divide it by the number of average outstanding shares. EPS is usually presented in two different ways: basic and diluted. Fully diluted Earnings per Share takes into account effects of warrants, options, and convertible securities and is generally viewed by analysts as a more accurate measure.
Current Infinity Pharmaceuticals Earnings Per Share | (0.45) X |
Most of Infinity Pharmaceuticals' fundamental indicators, such as Earnings Per Share, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Infinity Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Earnings per Share is one of the most critical measures of the firm's current share price and is used by investors to determine the overall company profitability, especially when compared to the EPS of similar companies.
CompetitionAccording to the company disclosure, Infinity Pharmaceuticals has an Earnings Per Share of -0.45 times. This is 105.38% lower than that of the Biotechnology sector and 90.61% lower than that of the Health Care industry. The earnings per share for all United States stocks is 114.42% higher than that of the company.
Infinity Earnings Per Share Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Infinity Pharmaceuticals' direct or indirect competition against its Earnings Per Share to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Infinity Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Infinity Pharmaceuticals by comparing valuation metrics of similar companies.Infinity Pharmaceuticals is currently under evaluation in earnings per share category among related companies.
Infinity Fundamentals
| Return On Equity | -35.21 | |||
| Return On Asset | -0.61 | |||
| Operating Margin | (15.70) % | |||
| Current Valuation | (9.46 M) | |||
| Shares Outstanding | 90.76 M | |||
| Shares Owned By Insiders | 2.36 % | |||
| Shares Owned By Institutions | 23.48 % | |||
| Number Of Shares Shorted | 2.21 M | |||
| Price To Earning | (1.63) X | |||
| Price To Book | 8.03 X | |||
| Price To Sales | 19.29 X | |||
| Revenue | 2.59 M | |||
| Gross Profit | (31.38 M) | |||
| EBITDA | (44.84 M) | |||
| Net Income | (44.37 M) | |||
| Cash And Equivalents | 56.58 M | |||
| Cash Per Share | 0.63 X | |||
| Total Debt | 917 K | |||
| Debt To Equity | 0.13 % | |||
| Current Ratio | 4.16 X | |||
| Book Value Per Share | (0.41) X | |||
| Cash Flow From Operations | (42.43 M) | |||
| Short Ratio | 0.31 X | |||
| Earnings Per Share | (0.45) X | |||
| Price To Earnings To Growth | (0.05) X | |||
| Target Price | 0.3 | |||
| Number Of Employees | 30 | |||
| Beta | 1.38 | |||
| Market Capitalization | 2.63 M | |||
| Total Asset | 42.15 M | |||
| Retained Earnings | (855.95 M) | |||
| Working Capital | 26.67 M | |||
| Current Asset | 254.7 M | |||
| Current Liabilities | 70.06 M | |||
| Z Score | -29.4 | |||
| Net Asset | 42.15 M |
About Infinity Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Infinity Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Infinity Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Infinity Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Infinity Pharmaceuticals in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Infinity Pharmaceuticals' short interest history, or implied volatility extrapolated from Infinity Pharmaceuticals options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in census. Note that the Infinity Pharmaceuticals information on this page should be used as a complementary analysis to other Infinity Pharmaceuticals' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Fundamentals Comparison module to compare fundamentals across multiple equities to find investing opportunities.
Other Consideration for investing in Infinity Stock
If you are still planning to invest in Infinity Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Infinity Pharmaceuticals' history and understand the potential risks before investing.
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation |